CD123 positive refractory or relapsed Acute Myeloid Leukemia
Conditions
Interventions
case series:CD123+CART -cell
Sponsors
Department of hematology, Tianjin First Central Hospital
Eligibility
Sex/Gender
All
Age
5 Years to 70 Years
Inclusion criteria
Inclusion criteria: Acute myeloid leukemia (not APL) with recurrence in patients aged 5-70 years (according to 2016 WHO diagnostic criteria) including: 1) Recurrence after hematopoietic stem cell transplantation; 2) Flow cytometric detection of CD123 expression in bone marrow abnormal cells was greater than or equal to 90%; 3) The survival time was expected to be more than 3 months; 4) The activity status score of the eastern United States tumor cooperative group(ECOG) was 0-2 points.
Exclusion criteria
Exclusion criteria: 1) Pregnancy and nursing females; 2) Participation in a prior investigational study within 3 months prior to enrollment; 3) Abnormal liver and kidney function: The definition is that serum aminotransferase and bilirubin are more than 1.5 times the upper limit of normal value; 4) Patients with poor compliance; 5) Other situations we think not eligible for participation in the research; 6) Positive HIV antibodies and syphilis antibodies; 7) Patients with other major diseases; 8) Poor physical condition; 9) Patients with mental illness; 10) Patients with drug abuse or addiction; 11) With serious organ dysfunction and uncontrolled infection.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Overall Surviva;Progress Free Survival;Complete Response;minimal residual disease;toxic and adverse effects; | — |
Countries
China
Contacts
Public ContactZhao Mingfeng
Department of hematology, Tianjin First Central Hospital
Outcome results
None listed